Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To compare the independently assessed progression-free survival following treatment with neratinib in combination with paclitaxel versus trastuzumab plus paclitaxel in subjects who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer.
Critère d'inclusion
- ErbB2 Positive Locally Recurrent or Metastatic Breast Cancer